| Name | Title | Contact Details |
|---|---|---|
Luke Gordon |
Vice President of Network Development | Profile |
Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE`s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy`s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth
Standard Process Inc is a Palmyra, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
X-37 is a pharmaceutical discovery and development company
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.